Phathom Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Phathom Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 94% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 93% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-285.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 93% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-257.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 94% of Healthcare companies in United States.
Cash Cushion Ratio
−14%Debt, after subtracting cash, equals 14% of its market value (net debt).
Lower than 81% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Phathom Pharmaceuticals, Inc. made a loss over the last year. Phathom Pharmaceuticals, Inc. owes $2.05 for every $1 it owns. Phathom Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPhathom Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-1.65Phathom Pharmaceuticals, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$567 MThe total market value of all of Phathom Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 56% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativePhathom Pharmaceuticals, Inc.'s net worth is negative ($344 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
2.05×Phathom Pharmaceuticals, Inc. owes $2.05 for every $1 it owns, so it owes more than it owns, higher than 96% of Healthcare companies in United States.
Dividend yield
NonePhathom Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+217%Revenue rose 217% in the year to Dec 2025.
Profit growth
LossPhathom Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-126.3%Phathom Pharmaceuticals, Inc. lost $126 for every $100 of revenue.
Interest cover
Not coveredPhathom Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtPhathom Pharmaceuticals, Inc. had $82 M more debt than cash (net debt) at Dec 2025.
Questions
How much does Phathom Pharmaceuticals, Inc. owe compared with what it owns?
Phathom Pharmaceuticals, Inc. owes $2.05 for every $1 it owns, so it owes more than it owns, higher than 96% of Healthcare companies in United States.
Does Phathom Pharmaceuticals, Inc. pay a dividend?
No. Phathom Pharmaceuticals, Inc. does not currently pay a dividend.
Is Phathom Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 217% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.